Nitric oxide (NO) produced by the NO synthase (NOS), a family of enzymes such as inducible NOS (iNOS), has been suggested to play an important role in tumor bioloty. We immunohistochemically examined iNOS and p53 protein expression in 105 patients with esophageal squamous cell carcinoma (ESCC). Direct sequence analysis for the p53 gene was performed in 51 of 105 tumors. In total, 56 of 105 (53.3%) tumors exhibited intracytoplasmic staining for anti-iNOS antibody, including 17 (16.2%) cases of homogeneous and intense immunostaining (++) and 39 (37.1%) of heterogeneous staining (+). Of 62 p53 protein-positive tumors, 40 (63.5%) were positive for iNOS, and of 43 p53 protein-negative tumors, 27 (62.8%) were negative for iNOS. Of 34 iNOS-positive tumors, 23 (67.6%) carried a p53 gene mutation, and of 17 iNOS-negative tumors, 12 (70.6%) had wild-type p53 gene. There was a significant relationship between iNOS immunoreactivity and p53 protein overexpression (p = 0.0058) as well as p53 mutation frequency (p = 0.0163). No association was found between iNOS immunoreactivity and p53 mutation type, any clinicopathological factor and patient prognosis. Our in vivo findings suggest that iNOS activity might be associated with p53 alteration and contribute to tumorigenesis in ESCC.

Keywords:
Esophageal squamous cell carcinoma, Inducible nitric oxide synthase, p53, Immunohistochemistry
1.
Schmidt HHHW, Walter U: NO at work. Cell 1994;78:919–925.
2.
Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109–142.
3.
Knowles RG, Moncada S: Nitric oxide synthase in mammals. Biochem J 1994;298:249–258.
4.
Yagihashi N, Kasajima H, Sugai S, Matsumoto K, Ebina Y, Morita T, Murakami T, Yagihashi S: Increased in situ expression of nitric oxide synthase in human colorectal cancer. Virchows Arch 2000;436:109–114.
5.
Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y: Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in situ and invasive breast carcinomas. Clin Cancer Res 2000;6:2408–2416.
6.
Wolf H, Haeckel C, Roessner A: Inducible nitric oxide synthase expression in human urinary bladder cancer. Virchows Arch 2000;437:662–666.
7.
Tanaka H, Kijima H, Tokunaga T, Tajima T, Himeno S, Kenmochi T, Oshiba G, Kise Y, Nishi T, Chino O, Shimada H, Machimura T, Tanaka M, Tajima T, Makuuchi H: Frequent expression of inducible nitric oxide synthase in esophageal squamous cell carcinoma. Int J Oncol 1999;14:1069–1073.
8.
Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S: Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994;54:1352–1354.
9.
Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S: Nitric oxide synthase activity in human breast cancer. Br J Cancer 1995;72:41–44.
10.
Aaltomaa SH, Lipponen PK, Viitanen J, Kankkunen JP, Ala-Opas MY, Kosma VM: The prognostic value of inducible nitric oxide synthase in local prostate cancer. BJU Int 2000;86:234–239.
11.
Jenkins DC, Charles IG, Thomsen LL, Moss DW, Holmes LS, Baylis SA, Rhodes P, Westmore K, Emson PC, Moncada S: Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA 1995;92:4392–4396.
12.
Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK: Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 1999;81:889–896.
13.
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817–825.
14.
Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849–852.
15.
Ambs S, Bennett WP, Merriam WG, Ogunfusika MO, Oser SM, Harrington AM, Shields PG, Felley-Bosco E, Hussain SP, Harris CC: Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. J Natl Cancer Inst 1999;91:86–88.
16.
Fujimoto H, Sasaki J, Matsumoto M, Suga M, Ando Y, Iggo R, Tada M, Saya H, Ando M: Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn J Cancer Res 1998;89:696–702.
17.
Hayashi H, Kuwahara M, Fujisaki N, Furihata M, Ohtsuki Y, Kagawa S: Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Oncol Rep 2001;8:1275–1279.
18.
Blot WJ: Esophageal cancer trends and risk factors. Semin Oncol 1994;21:403–410.
19.
Kato H, Miyazaki T, Yoshikawa M, Nakajima M, Fukai Y, Tajima K, Masuda N, Tsutsumi S, Tsukada K, Nakajima T, Kuwano H: Nitrotyrosine in esophageal squamous cell carcinoma and relevance to p53 expression. Cancer Lett 2000;29:121–127.
20.
Phukan RK, Ali MS, Chetia CK, Mahanta J: Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India: Br J Cancer 2001;85:661–667.
21.
Sepehr A, Taniere P, Martel-Planche G, Zia’ee AA, Rastgar-Jazii F, Yazdanbod M, Etemed-Moghadam G, Kamangar F, Saidi F, Hainaut P: Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran: Oncogene 2001;20:7368–7374.
22.
Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM: Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol 1999;161:630–634.
23.
Klotz T, Bloch W, Jacobs G, Niggemann S, Engelmann U, Addicks K: Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 1999;54:416–419.
24.
Tschugguel W, Pustelnik T, Lass H, Mildner M, Weninger W, Schneeberger C, Jansen B, Tschachler E, Waldhor T, Huber JC, Pehamberger H: Inducible nitric oxide synthase (iNOS) expression may predict distant metastasis in human melanoma. Br J Cancer 1999;79:1609–1612.
25.
Hajri A, Metzger E, Vallat F, Coffy S, Flatter E, Evrard S, Marescaux J, Aprahamian M: Role of nitric oxide in pancreatic tumour growth: In vivo and in vitro studies. Br J Cancer 1998;78:841–849.
26.
Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC: Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996;93:2442–2447.
27.
Ambs S, Hussain SP, Harris CC: intractive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression. FASEB J 1997;11:443–448.
28.
Murata J, Tada M, Iggo RD, Sawamura Y, Shinohe Y, Abe H: Nitric oxide as a carcinogen: Analysis by yeast functional assay of inactivating p53 mutations induced by nitric oxide. Mutat Res 1997;379:211–218.
29.
Sarbia M, Porschen R, Borchard F, Horstmann O, Willers R, Gabbert HE: p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:2218–2223.
30.
Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H, Yamaguchi H, Gotoda T, Muro K, Matsumara Y: No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol 1999;72:94–98.
© 2003 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.